Skip to Content
You are currently on the new version of our website. Access the old version .
  • Indexed in
    Scopus
  • 24 days
    Submission to First Decision
  • 5 days
    Acceptance to Publication

Drugs and Drug Candidates

Drugs and Drug Candidates is an international, peer-reviewed, open access journal on drug discovery, development, and knowledge, published quarterly online by MDPI.

Get Alerted

Add your email address to receive forthcoming issues of this journal.

All Articles (218)

  • Article
  • Open Access

Background/Objectives: Multi-target claims in computational studies of Alzheimer’s disease rest on docking scores compared across receptors, although receptor-specific baselines are rarely established. We asked whether such concordance reflects binding-site complementarity or the calculation. Methods: 264 flavonoids were filtered by predicted absorption, distribution, metabolism, excretion and toxicity (ADMET) and prioritized by predicted kinase activity (49 retained); network pharmacology identified eight Alzheimer-associated core targets. Glide extra-precision (XP) docking was validated at each receptor by re-docking the co-crystallized ligand, whose score served as a receptor-specific baseline. ATP pockets were compared structurally, and the analysis was repeated for 122 unrelated compounds. Results: Baselines spanned −2.515 to −10.920 kcal/mol, exceeding the differences between compounds; normalization reordered the campaign completely (Spearman ρ = 0.078). Scores correlated between all kinase pairs (mean r = 0.693) yet showed no detectable relationship with pocket sequence identity (Mantel p = 0.29) or any SiteMap descriptor, whereas free hydroxyl count—the dominant marker of a polarity axis—explained 50–80% of the variance, its removal collapsing the correlation to 0.080. The diverse library reproduced stronger agreement (mean r = 0.776) on one latent axis carrying 81.4% of the variance, again showing no relationship to pocket similarity (p = 0.86). Robinetin ranked first at AKT1 after normalization and stayed in the ATP cleft throughout two independent 100 ns trajectories (Molecular Mechanics/Generalized Born Surface Area, MM-GBSA, −137.2 ± 20.7 kcal/mol), although hydrogen-bond occupancies differed between runs. Conclusions: Concordant docking scores reflect the calculation rather than binding-site complementarity and cannot alone support a multi-target mechanism; receptor normalization and ligand-descriptor deconvolution are minimum requirements.

Drugs Drug Candidates

14 November 2026

Venn diagram of the intersection between Alzheimer’s disease-associated genes (List 1) and predicted flavonoid targets (List 2), showing 76 common targets.
  • Article
  • Open Access

Exploring Natural Compounds for HIV Treatment: A Virtual Screening Study

  • Daniela Peres Martinez and
  • Frederico Schmitt Kremer

Background: Bioprospecting for natural compounds has led to the discovery of diverse molecules that have become effective drugs for treating various diseases. However, exploring these compounds remains challenging because of the vast, uncatalogued global biodiversity and the structural complexity of the identified molecules. Virtual screening (VS) has emerged as an effective strategy to support molecular discovery, significantly reducing drug development time and costs. Methods: We virtually screened a natural compound library using quantitative structure-activity relationship (QSAR) models and molecular docking assays, targeting the human immunodeficiency virus (HIV) and its relevant clinical targets. We docked against 11 structures using a single protocol, tested its ability to reproduce a known binding mode by redocking every co-crystallized ligand, and docked each compound alongside 21 established inhibitors of the same sites so predictions could be read against a clinical baseline rather than in isolation. We evaluated the most promising molecules for pharmacokinetic properties and the toxicity of both the parent compounds and their predicted secondary metabolites. Results: In terms of docking score, the compounds identified here do not outperform the approved drugs of the pockets they occupy; what they show is interaction fidelity, the clearest case being a prenylated flavonoid that reproduces the complete interaction fingerprint of nevirapine in the non-nucleoside pocket of reverse transcriptase at a score 1.0 kcal/mol weaker. Conclusions: We present these compounds as scaffolds for optimization rather than candidates for direct testing and report the pockets where our protocol could not be validated so readers do not overinterpret the corresponding predictions.

Drugs Drug Candidates

13 November 2026

Predicted binding modes of the best-scoring natural compound in each pocket whose co-crystallized ligand the docking protocol reproduces within 2 Å. Each row is one complex, and the three panels read from left to right: the two poses ray-traced together in the pocket, the screened compound in red and that pocket’s established binder in blue; the 2D interaction map of the screened compound; and the 2D interaction map of the established binder. In the 2D maps, a solid residue border marks a contact made by both molecules and a dashed border one made by only that molecule; an asterisk marks a residue of the site defined in Table 1. All contacts were classified with PLIP from the docked poses. (a) 8-Prenylkaempferol (ZINC000014762765) in 3LP0 (HIV-1 reverse transcriptase): ΔG = −10.0 kcal/mol, LE = −0.38, reproducing 100% of the interaction fingerprint of nevirapine (8 of 8 contacts), which scores ΔG = −11.0 kcal/mol in the same pocket. (b) (2E)-3-(furan-2-yl)-N-[4-(2-oxo-2H-chromen-3-yl)phenyl]prop-2-enamide (ZINC000000843690) in 5IVQ (HIV-1 protease): ΔG = −9.1 kcal/mol, LE = −0.34, reproducing 36% of the interaction fingerprint of darunavir (4 of 11 contacts), which scores ΔG = −10.1 kcal/mol in the same pocket. (c) Capillarisin (ZINC000005998556) in 3CZD (Glutaminase): ΔG = −7.2 kcal/mol, LE = −0.32, reproducing 71% of the interaction fingerprint of DON (5 of 7 contacts), which scores ΔG = −5.2 kcal/mol in the same pocket.
  • Review
  • Open Access

Recently, protein degraders such as Proteolysis Targeting Chimeras (PROTACs) are gaining traction as valuable alternatives to traditional small-molecule inhibitors of various proteins, especially kinases implicated in cancers. PROTACs are heterobifunctional ligands that bind to the protein of interest while recruiting the cellular ubiquitin-proteasomal system to induce the selective degradation of the bound protein. By being catalytic in nature, PROTACs shift the focus from traditional occupancy-driven inhibition, thereby achieving protein degradation at lower and safer doses. Additionally, PROTACs have also found success over small-molecule inhibitors in targeting drug-resistant and undruggable protein targets. While initially developed for proteins of oncological and immunological interest, recent advances, albeit to a lesser extent, have expanded Targeted Protein Degradation (TPD) technology into the antiviral research space. Generally, research has focused on achieving antiviral effect by degrading either viral proteins or host proteins essential to virus survival. Herein, the general principles and recent advances of small-molecule-based degraders (for proteins or RNA) are summarized along with their applications in the field of antiviral drug discovery. While several limitations need to be addressed, the remarkable progress and expansion of protein degraders to the antiviral field is paving the way for a promising new modality of antiviral therapy.

Drugs Drug Candidates

11 November 2026

The mechanism of action of PROTACs recruiting the UPS. Proteins are ubiquitinated by the catalysis of three enzymes. Firstly, ubiquitin (Ub) is activated by the E1 ubiquitin-activating enzyme using ATP, resulting in an ubiquitin-adenylate that is then bound to a Cys residue of E1 via a thioester bond. Following this, a transthioesterification reaction allows the transfer of Ub from E1 to the catalytic Cys of E2 ubiquitin-conjugating enzyme. The ternary complex formed between E2, E3 ubiquitin ligase and the POI allows for the transfer of Ub from E2 to the POI. The POI can be polyubiquitinated by additional cycles of this process and ultimately the POI is tagged with a poly-ubiquitin sequence that can be recognized and subsequently degraded by the 26S proteasome. The image also shows a PROTAC composed of an E3 ligase ligand attached to the POI ligand via a linker. Reprinted from “PROTAC: Proteolytic Targeting Chimera”. Created in BioRender. Argade, M. (2026) https://BioRender.com/h68vnmo.
  • Review
  • Open Access

Phytochemical Composition and Colorectal Anticancer Activity of the Genus Solanum L.: An Updated Review

  • Pablo Vinícius Soares de Santana,
  • Heivila Monique da Silva Alexandre and
  • Juan Carlos Ramos Gonçalves
  • + 3 authors

Research on the genus Solanum L. has expanded significantly due to its potential as a source of bioactive secondary metabolites for oncological applications. Colorectal cancer (CRC) remains a major global health challenge, and traditional chemotherapy is often limited by severe side effects and resistance mechanisms. This review synthesizes current scientific literature regarding the phytochemical composition and in vitro colorectal anticancer activity of plants belonging to the genus Solanum L. The available studies encompass diverse experimental approaches, including crude extracts, bioactive fractions, isolated compounds, synergistic combinations, and novel nanoparticle delivery systems. Phytochemical analyses highlight alkaloids, glycoalkaloids, and phenolic compounds as the primary bioactive constituents responsible for suppressing CRC cell viability and inducing cytotoxic effects. Emerging strategies, such as green-synthesized nanoparticles and synergistic formulations with established or natural agents, represent promising avenues to enhance therapeutic efficacy and lower toxicity. Overall, Solanum L. species harbor a broad array of promising candidate molecules that warrant further mechanistic and in vivo investigation for CRC drug discovery.

Drugs Drug Candidates

1 November 2026

Herbarium specimens representing eleven species of Solanum L. (A) S. nigrum (K001871184); (B) S. elaeagnifolium (K001336352); (C) S. lycopersicum (K000265997); (D) S. tuberosum (K000914631); (E) S. lyratum (K000788319); (F) S. incanum (S25-6841); (G) S. xanthocarpum (LY0455320); (H) S. lycocarpum (S09-23099); (I) S. septemlobum (S09-35301); (J) S. sessiliflorum (K001897638); and (K) S. quitoense (K001058542). Image credits: Royal Botanic Gardens, Kew (A–E,J,K); Mia Ehn (F), Daniel Andersson (H), and Åsa Dalsätt (I), Swedish Museum of Natural History; and Picture (G), specimen held at the Université Claude Bernard Lyon 1 herbarium, with rights held by RECOLNAT (ANR-11-INBS-0004). All photographs are licensed under Creative Commons Attribution 4.0 International. Images were cropped, resized, and arranged within circular panels.

Highly Accessed Articles

News & Conferences

Latest Issues

Open for Submission

Journal Sections

XFacebookLinkedIn
Drugs Drug Candidates - ISSN 2813-2998